Navigation Links
Aida Announces New Anti-Cancer Drug Under Development
Date:4/18/2008

SANTA MONICA, Calif., April 18 /PRNewswire-FirstCall/ -- Aida Pharmaceuticals, Inc. (OTC Bulletin Board: AIDA) (hereinafter referred to as "Aida") today announced that it is developing a potential cancer drug that seeks to trigger cell death in certain types of cancer. Vasostatin-Apo2L, a pre-clinical product being developed by Aida's Shanghai Qiaer subsidiary, is a recombinant fusion protein that integrates the function of extracted fragments of Vasostatin, an inhibitor of angiogenesis and tumor growth, with the function of Rh-Apo2L, which induces the apoptosis of cancer cells. It has shown positive results in the lab. Aida's researchers believe that the integration of Vasostatin-Apo2L will have higher efficacy in certain cancer treatments than currently prescribed methods.

Aida estimates that Vasostatin will have a target market of 80,000-100,000 patients per year after it is successfully brought to market and this will contribute significantly to Aida's revenue.

Vasostatin-Apo2L is developed by the same research team that created Rh-Apo2L. Rh-Apo2L has successfully completed its Phase 2 clinical testing and is going to file application with the PRC government's State Food and Drug Administration to start the Phase III trials. The development of Vasostatin-Apo2L will benefit strongly from the experience garnered in the research, manufacturing and distribution of Rh-Apo2L.

About Aida Pharmaceuticals

Aida Pharmaceuticals is a product-focused pharmaceuticals company engaged in the formulation, clinical testing, registration, manufacture, sales and marketing of advanced pharmaceutical and genetic products in mainland China. The Company's mission is to discover, develop and market meaningful new therapies that improve human health. Aida Pharmaceuticals, in operation since March 1999, is headquartered in Hangzhou, China with manufacturing, distribution and sales points throughout mainland China. Aida is GMP certified in China and ISO90
'/>"/>

SOURCE Aida Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 2015 UPM Pharmaceuticals, a division of Gregory ... Pharmaceuticals to manufacture Flibanserin 100 mg tablets. Sprout has ... first drug approved to treat hypoactive sexual desire disorder ... The tablets will be manufactured at UPM,s ... . Dr. John M. Gregory ...
(Date:3/4/2015)... March 4, 2015 From March 8-11, ... 2015 Distribution Management Conference and Expo in ... HDMA,s largest supply chain education event, attended by ... who keep the pharmaceutical distribution industry moving. Attracting ... and legislative issues important to healthcare distribution and ...
(Date:3/4/2015)... 4, 2015 Aethlon Medical, Inc. (OTCQB:AEMD), the pioneer ... and cancer, today announced that James A. Joyce ... corporate overview at the 27th Annual ROTH Conference on ... Laguna Niguel, California . To learn more ... A live webcast of the presentation will ...
Breaking Medicine Technology:UPM Pharmaceuticals to Manufacture Sprout Pharmaceuticals' Flibanserin Tablets 2UPM Pharmaceuticals to Manufacture Sprout Pharmaceuticals' Flibanserin Tablets 3Aethlon Medical to Present at the 27th Annual ROTH Conference 2
... Biosciences, Inc., a privately held company leading the ... announces one poster presentation and two oral presentations ... meeting on November 14, 2011 during the 9:00 ... presentations highlight results from Regado,s pipeline of antithrombotic ...
... GenturaDx today announced that it will present data from alpha ... Pathology 2011 Annual Meeting on Friday, November 18 from 2:15 ... Of Assay Performance Between Cell Culture And A Rapid Automated ... will address the capability of the GenturaDx IDbox™ System to ...
Cached Medicine Technology:Regado Biosciences, Inc. Presents Three Abstracts Pertaining to its Pipeline of Reversible Antithrombotic Agents, Including the Substudy Analyses of its Phase 2b RADAR Trial for REG1, its Lead Product Candidate, at the American Heart Association (AH 2Regado Biosciences, Inc. Presents Three Abstracts Pertaining to its Pipeline of Reversible Antithrombotic Agents, Including the Substudy Analyses of its Phase 2b RADAR Trial for REG1, its Lead Product Candidate, at the American Heart Association (AH 3Regado Biosciences, Inc. Presents Three Abstracts Pertaining to its Pipeline of Reversible Antithrombotic Agents, Including the Substudy Analyses of its Phase 2b RADAR Trial for REG1, its Lead Product Candidate, at the American Heart Association (AH 4GenturaDx to Host Poster Presentation at Association for Molecular Pathology 2011 Annual Meeting 2
(Date:3/4/2015)... The federal litigation established for Lipitor ... caused patients to develop Type 2 diabetes continues to ... South Carolina. According to court documents, the proceeding’s next ... at 10:00 a.m. In advance of the Conference, the ... report to the Court by March 19, 2015. (In ...
(Date:3/4/2015)... VIENNA, Austria (PRWEB) March 04, 2015 ... to reduce subjectivity in density assessment and help ... focus of numerous abstracts accepted for presentation at ... 3-8, 2015. Ten abstracts - eight posters ... of Volpara Solutions’ automated breast density and quantitative ...
(Date:3/4/2015)... More than a year after announcing ... with low testosterone treatments ( http://www.testosteronelawsuithub.com/ ), the U.S. ... now require manufacturers to warn patients that this class ... and strokes. In a Drug Safety Communication ... it was requiring testosterone manufacturers to update the drugs’ ...
(Date:3/4/2015)... The print component of “Organic Living” ... Chronicle with a circulation of approximately 173,000 copies and ... is distributed nationally through a vast social media strategy ... partner outlets. To explore the digital version of the ... composed of heat-dried microbes that have digested the organic ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 The ... $236.8 billion in 2014 and is estimated to ... CAGR of 4.0% from 2014 to 2019. , ... Gas Market for an analysis of industry trends, ... The global liquefied petroleum gas market is classified ...
Breaking Medicine News(10 mins):Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 2Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 3Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 2Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 3Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 4Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 5Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 3Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 4Health News:The Global Liquefied Petroleum Gas Market is Estimated to Reach $288.7 Billion by 2019 - A Report by MicroMarket Monitor 2Health News:The Global Liquefied Petroleum Gas Market is Estimated to Reach $288.7 Billion by 2019 - A Report by MicroMarket Monitor 3
... Specialized one- and two-year Indiana University graduate ... number of health information technology specialists in Indiana ... thanks in part to Recovery Act funding. Two ... learning opportunities. In collaboration with the Regenstrief ...
... HIV could help to develop a vaccine to build antibodies, ... has found. By investigating the action of the human ... to identify that the virus evolves to evade or ,escape, ... Melbourne and one of the senior authors on the paper ...
... pylori , a common stomach bacteria, minimizes the effects of ... of Michigan Medical School scientists. The study published in ... of investigators assembled by senior author John Y. Kao, M.D. ... professor in U-M,s Department of Internal Medicine. The findings indicate ...
... 4, 2011) Autism Speaks, the world,s largest autism ... announced the top awards for "Autism Connects", the international ... by student competitors selected by a juried panel demonstrate ... (ASD) to better connect with the world around them, ...
... 5 (HealthDay News) -- In people with advanced kidney cancer, ... is working, with high blood pressure linked to longer survival, ... of 544 people being treated with the drug sunitinib (Sutent) ... maximum systolic blood pressure reached 140 mmHg or higher survived ...
... New Rochelle, NY, May 5, 2011When children or adolescents ... the disorder, it may impair their ability to manage ... asthma-related anxiety is described in an article in ... published by Mary Ann Liebert, Inc. The article is ...
Cached Medicine News:Health News:IU-Regenstrief programs targeted to alleviate shortage of health IT workforce 2Health News:DNA from common stomach bacteria minimizes effects of colitis, U-M study says 2Health News:Autism Speaks and Core77 Magazine name winners of 'Autism Connects' design challenge 2Health News:Autism Speaks and Core77 Magazine name winners of 'Autism Connects' design challenge 3Health News:Autism Speaks and Core77 Magazine name winners of 'Autism Connects' design challenge 4Health News:Blood Pressure May Hint at Kidney Cancer Outcome 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: